Facility in Sudair Industrial City is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions in Saudi Arabia
Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures
The near-term commencement of clinical studies is expected to align with recent WHO tuberculosis recommendations for near-point-of-care molecular testing and utilizing tongue swab samples
Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to...
Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro ® and SARAGENE ® product...
Co-Dx to join WTC Utah and other Utah legislative and industry delegates March 19-22 in Seoul, South Korea
SALT LAKE CITY , March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development...
SALT LAKE CITY , March 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development...
SALT LAKE CITY , Feb. 9, 2026 /PRNewswire/ -- Co-Diagnostics, Inc . (OTC: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development...
CDSCO license on Form MD-5 authorizes CoSara to manufacture PCR Pro instrument in its Ranoli, India facility for sale or distribution